英国医学真菌学会严重真菌病诊断最佳实践建议:2025年更新
英国医学真菌学会召集专家组更新2015年最佳实践指南,组织病理学和影像学检查建议不变,针对真菌学检测新增或强化推荐,包括肺孢子菌PCR、1,3-β-D-葡聚糖检测、高通量呼吸道样本培养、ICU和慢性呼吸病患者的曲霉抗原/抗体检测、特定情境下的念珠菌PCR和毛霉目PCR、泛真菌PCR及测序鉴定、泊沙康唑和艾沙康唑治疗药物监测,建议以可审核标准呈现。
要点
- 组织病理学和影像学检查建议沿用2015年标准,本次未更新。
- 新增或强化推荐包括肺孢子菌PCR、1,3-β-D-葡聚糖检测、高通量呼吸道样本培养。
- 推荐在ICU和慢性呼吸病患者(包括哮喘)中开展曲霉抗原或抗体检测。
核心结论
- 专家组基于近期证据更新2015年指南,组织病理学和影像学建议不变,多项真菌学检测新增或强化推荐,建议以可审核标准呈现以促进实施和质量改进。
研究设计与样本
- 英国医学真菌学会召集专家组更新2015年最佳实践指南,纳入近期证据,每种真菌学检测附专项评论和表格并列出预期周转时间(从样本采集到报告)。
诊断标准与关键数值
- 推荐使用肺孢子菌PCR。
- 推荐对疑似侵袭性念珠菌病和肺孢子菌肺炎检测1,3-β-D-葡聚糖。
- 推荐采用更高体积的呼吸道样本培养。
- 推荐在扩展的临床脆弱人群中检测曲霉抗原或抗体,包括重症监护病房患者和慢性呼吸病患者(包括哮喘)。
- 推荐在特定情境下使用念珠菌PCR和毛霉目PCR,并对显微镜或组织病理阳性标本采用泛真菌PCR和DNA测序鉴定真菌。
临床应用与阅片要点
- 在特定情境下可使用念珠菌PCR和毛霉目PCR。
- 对显微镜或组织病理阳性标本可采用泛真菌PCR和DNA测序鉴定真菌。
- 治疗药物监测推荐纳入泊沙康唑和艾沙康唑。
- 推荐将诊断检测与抗真菌药物管理和常见临床场景相整合。
局限性
- 推荐主要针对成人及英国实践,文中讨论了在儿科人群和全球范围内的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The fungal diagnostic landscape is evolving; whereas previously, traditional culture-based methods dominated, most invasive fungal disease is now diagnosed with non-culture-based tests, including direct microscopy, antigen, antibody, and molecular assays, supported by histopathology and radiology. Access to and turnaround time of diagnostic tests and their clinical implementation varies across the UK. The British Society for Medical Mycology convened an expert group to update its 2015 best practice guidance. Guidance on histopathology and radiology investigations remain unchanged from the 2015 standards of care. For each mycological test, we include test-specific commentaries and accompanying tables, with expected turnaround times (sample collection to reporting). Based on recent evidence, new or stronger recommendations include use of Pneumocystis PCR; 1,3-β-D-glucan testing for suspected invasive candidiasis and Pneumocystis pneumonia; higher volume respiratory sample cultures; Aspergillus antigen or antibody-based testing in expanded clinically vulnerable populations, including patients in intensive care units and patients with chronic respiratory disease (including asthma); use of Candida PCR and Mucorales PCR in specific contexts; pan-fungal PCR and DNA sequencing for fungal identification from positive microscopy or histopathology specimens; and inclusion of posaconazole and isavuconazole in therapeutic antifungal monitoring recommendations. We discuss integration of diagnostic tests with antifungal stewardship and common clinical scenarios. Although recommendations focus on adults and UK practice, use in paediatric populations and worldwide applicability is discussed. Recommendations are presented as auditable standards to facilitate implementation and quality improvement measures. An emphasis on integration of combined diagnostics with antifungal stewardship and clinical pathways extends guideline relevance beyond microbiology laboratories to clinicians investigating patients with multimorbidity and suspected fungal disease within increasingly complex health-care systems.
引用
- Schelenz S, Abdolrasouli A, Armstrong-James D, et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update. Lancet Infect Dis. 2025. PMID: 41232547. doi:10.1016/S1473-3099(25)00550-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。